BIOTE CORP -A (BTMD) Fundamental Analysis & Valuation

NASDAQ:BTMD • US0906831039

Current stock price

1.53 USD
+0.09 (+6.25%)
At close:
1.53 USD
0 (0%)
After Hours:

This BTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BTMD Profitability Analysis

1.1 Basic Checks

  • BTMD had positive earnings in the past year.
  • BTMD had a positive operating cash flow in the past year.
  • Of the past 5 years BTMD 4 years were profitable.
  • Of the past 5 years BTMD 4 years had a positive operating cash flow.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M -60M

1.2 Ratios

  • BTMD has a Return On Assets of 25.13%. This is amongst the best in the industry. BTMD outperforms 98.44% of its industry peers.
  • With an excellent Return On Invested Capital value of 44.85%, BTMD belongs to the best of the industry, outperforming 99.48% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for BTMD is significantly above the industry average of 12.98%.
  • The last Return On Invested Capital (44.85%) for BTMD is above the 3 year average (32.37%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROIC 44.85%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • With an excellent Profit Margin value of 14.07%, BTMD belongs to the best of the industry, outperforming 86.98% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BTMD has declined.
  • BTMD has a better Operating Margin (18.50%) than 86.46% of its industry peers.
  • In the last couple of years the Operating Margin of BTMD has declined.
  • BTMD has a Gross Margin of 71.46%. This is in the better half of the industry: BTMD outperforms 79.17% of its industry peers.
  • BTMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

4

2. BTMD Health Analysis

2.1 Basic Checks

  • BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, BTMD has more shares outstanding
  • The number of shares outstanding for BTMD has been increased compared to 5 years ago.
  • The debt/assets ratio for BTMD has been reduced compared to a year ago.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 2.55 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • BTMD has a Altman-Z score of 2.55. This is in the better half of the industry: BTMD outperforms 67.71% of its industry peers.
  • The Debt to FCF ratio of BTMD is 4.43, which is a neutral value as it means it would take BTMD, 4.43 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BTMD (4.43) is better than 84.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Altman-Z 2.55
ROIC/WACC5.96
WACC7.52%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.22 indicates that BTMD should not have too much problems paying its short term obligations.
  • The Current ratio of BTMD (1.22) is worse than 77.60% of its industry peers.
  • BTMD has a Quick Ratio of 1.22. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.79, BTMD is doing worse than 82.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 0.79
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

6

3. BTMD Growth Analysis

3.1 Past

  • BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 277.27%, which is quite impressive.
  • The earnings per share for BTMD have been decreasing by -26.76% on average. This is quite bad
  • BTMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.22%.
  • BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.51% yearly.
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.65% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 8.86% on average over the next years. This is quite good.
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

8

4. BTMD Valuation Analysis

4.1 Price/Earnings Ratio

  • BTMD is valuated cheaply with a Price/Earnings ratio of 1.84.
  • Based on the Price/Earnings ratio, BTMD is valued cheaply inside the industry as 98.44% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.23, BTMD is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 6.00, the valuation of BTMD can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, BTMD is valued cheaper than 94.27% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.28, BTMD is valued rather cheaply.
Industry RankSector Rank
PE 1.84
Fwd PE 6
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • BTMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BTMD is cheaper than 97.40% of the companies in the same industry.
  • 98.96% of the companies in the same industry are more expensive than BTMD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.14
EV/EBITDA 4.04
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The decent profitability rating of BTMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.34%
EPS Next 3Y11.89%

0

5. BTMD Dividend Analysis

5.1 Amount

  • No dividends for BTMD!.
Industry RankSector Rank
Dividend Yield 0%

BTMD Fundamentals: All Metrics, Ratios and Statistics

BIOTE CORP -A

NASDAQ:BTMD (3/20/2026, 8:00:02 PM)

After market: 1.53 0 (0%)

1.53

+0.09 (+6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)05-05
Inst Owners63.61%
Inst Owner Change0.4%
Ins Owners10.06%
Ins Owner Change0%
Market Cap60.51M
Revenue(TTM)192.22M
Net Income(TTM)27.05M
Analysts81.82
Price Target4.94 (222.88%)
Short Float %5.15%
Short Ratio7.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)189.9%
Min EPS beat(2)17.65%
Max EPS beat(2)362.15%
EPS beat(4)4
Avg EPS beat(4)254.13%
Min EPS beat(4)17.65%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)90.98%
EPS beat(12)7
Avg EPS beat(12)15.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.53%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.5%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 1.84
Fwd PE 6
P/S 0.31
P/FCF 2.14
P/OCF 1.72
P/B N/A
P/tB N/A
EV/EBITDA 4.04
EPS(TTM)0.83
EY54.25%
EPS(NY)0.26
Fwd EY16.67%
FCF(TTM)0.72
FCFY46.82%
OCF(TTM)0.89
OCFY58.16%
SpS4.86
BVpS-1.48
TBVpS-1.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROCE 56.77%
ROIC 44.85%
ROICexc 72.95%
ROICexgc 117.64%
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
FCFM 14.74%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
ROICexc(3y)67.85%
ROICexc(5y)N/A
ROICexgc(3y)109.57%
ROICexgc(5y)N/A
ROCE(3y)40.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.74%
ROICexc growth 3YN/A
ROICexc growth 5Y-35.99%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
F-Score7
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Debt/EBITDA 2.57
Cap/Depr 187.03%
Cap/Sales 3.57%
Interest Coverage 4.51
Cash Conversion 89.73%
Profit Quality 104.75%
Current Ratio 1.22
Quick Ratio 0.79
Altman-Z 2.55
F-Score7
WACC7.52%
ROIC/WACC5.96
Cap/Depr(3y)157.42%
Cap/Depr(5y)165.61%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.48%
Profit Quality(3y)682.14%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%
EBIT growth 1Y-15.43%
EBIT growth 3YN/A
EBIT growth 5Y2.26%
EBIT Next Year51.43%
EBIT Next 3Y25.51%
EBIT Next 5Y17.45%
FCF growth 1Y-26.01%
FCF growth 3YN/A
FCF growth 5Y2.5%
OCF growth 1Y-22.21%
OCF growth 3YN/A
OCF growth 5Y5.89%

BIOTE CORP -A / BTMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 6 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 8 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


Can you provide the profitability details for BIOTE CORP -A?

BIOTE CORP -A (BTMD) has a profitability rating of 7 / 10.


How financially healthy is BIOTE CORP -A?

The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.


How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?

The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.